

MIHP Biweekly Update

January 29, 2024



Maternal Infant Health Program

- [Mark Your Calendar! February COP Webinar](#)
- [CDC Recommended Immunization Schedule](#)
- [Transforming Maternal Health \(Tamah\) Model](#)
- [Seasonal Administration of Maternal RSV Vaccine](#)
- [V-Safe Registration for COVID-19 Vaccines](#)
- [News from the Institute for the Advancement of Family Support Professionals](#)
- [Upcoming State of Michigan \(SOM\) Holidays](#)
- [Previously Released MIHP Updates](#)
- [Bi-Weekly Update Topic Submission](#)
- [MDHHS Publications](#)
- [Coordinator Directory](#)

Mark Your Calendar! February COP Webinar

The February Community of Practice will be held on Wednesday, February 14th, 2024 from 1:00PM - 2:30PM. The topic is Immunization Update, presented by Alissa Borowiak from MIHP and Hannah Forsythe, Ph.D, from the MDHHS Division of Immunization.

- Immunization Update [REGISTER HERE](#)



CDC Recommended Immunization Schedule

The Morbidity and Mortality Weekly Report (MMWR) has published two reports summarizing 2024 updates to CDC Immunization Schedules:

- [Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger—United States, 2024](#)
- [Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older—United States, 2024](#)

As a reminder, the [2024 Immunization Schedules for Clinicians](#) were published in November 2023.

The 2024 Child and Adolescent Immunization Schedule includes new recommendations for:

- respiratory syncytial virus (RSV) vaccine,
- respiratory syncytial virus (RSV) monoclonal antibody,
- Mpox vaccine,
- 20-valent pneumococcal conjugate vaccine, and
- pentavalent meningococcal vaccine.

The [2024 Adult Immunization Schedule](#) includes new recommendations for:

- respiratory syncytial virus (RSV) vaccine,
- Mpox vaccine, and
- pentavalent meningococcal vaccine.

Both schedules also include updated recommendations for 2023-2024 formula COVID-19 vaccine, influenza vaccines, and inactivated poliovirus vaccine (IPV).

Below are resources for patients to assist them with understanding which vaccines are recommended for adults and children:

- Adult Easy-to-Read Schedule ([English](#) and [Spanish](#))
- [Childhood and Adolescent Assessment Tool](#)
- [Vaccines You Need as an Adult](#)

CDC is updating the parent-friendly schedules and will notify you once they are available.

Transforming Maternal Health (Tamah) Model

In December, the federal Centers for Medicaid and Medicare Services (CMS) announced a new framework for supporting improved maternal healthcare delivery for Medicaid enrollees referred to as the [Transforming Maternal Health \(Tamah\)](#) Model.

Tamah is the newest CMS model designed to focus exclusively on improving maternal health care for people enrolled in Medicaid and Children's Health Insurance Program (CHIP). The model will support participating state Medicaid agencies (SMAs) in the development of a whole-person approach to pregnancy, childbirth, and postpartum care that addresses the physical, mental health, and social needs experienced during pregnancy. The goal of the model is to reduce disparities in access and treatment. The model aims to improve outcomes and experiences for mothers and their newborns, while also reducing overall program expenditures.

The model is projected to run for 10 years.

Seasonal Administration of Maternal RSV Vaccine

The Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP) recommend the [RSV vaccination \(Pfizer Abrysvo\) for pregnant people](#) during 32–36 weeks gestation using seasonal administration to protect infants against RSV-associated lower respiratory tract disease (LRTD) after birth. In most of the continental United States, the RSV vaccine should be given to pregnant people from September 1 through January 31, regardless of year-to-year circulation, when infants would be born during increased RSV activity, and the vaccination would provide the most benefits to the infant against RSV-associated LRTD after birth.

Jurisdictions that have different RSV seasonality from most of the continental United States, such as Alaska, southern Florida, Guam, Hawaii, Puerto Rico, the U.S.-affiliated Pacific Islands, and the U.S. Virgin Islands, may consider RSV vaccination of pregnant people after January 31. Infants born to unvaccinated mothers should receive nirsevimab, a long-acting monoclonal antibody that provides immediate protection to the infant against RSV-associated LRTD.

Recommendations for Healthcare Providers on the Seasonal Administration of the RSV Vaccine (Pfizer Abrysvo)

- In most of the continental United States, administer the maternal RSV vaccine (Pfizer Abrysvo) from September 1 through January 31.
 - Healthcare providers who administer the RSV vaccine to pregnant people after January 31 should encourage patients to check with their insurance plans on coverage details, as coverage and cost-sharing by private insurance plans may vary after January 31. Providers should consider submitting an insurance test claim to estimate out-of-pocket costs.
- In jurisdictions where seasonality differs from most of the continental United States, such as Alaska, southern Florida, Guam, Hawaii, Puerto Rico, the U.S.-affiliated Pacific Islands, and the U.S. Virgin Islands, healthcare providers should follow state, local, or territorial guidance on timing of administering the RSV vaccine (Pfizer Abrysvo) for pregnant people.
- CDC recommends protecting all infants against RSV-associated LRTD through either the RSV vaccine for pregnant people (Pfizer Abrysvo) or infant receipt of nirsevimab. Administration of both products is not needed for most infants.

For infants age less than 8 months born to unvaccinated mothers, healthcare providers should administer nirsevimab from October 1 through March 31; however, healthcare providers can administer nirsevimab outside of this timeframe based on local epidemiology.

For More Information:

- [Frequently Asked Questions about RSVpreF \(Abrysvo\) Vaccine for Pregnant People](#)
- [Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023](#)
- [Frequently Asked Questions about RSV Immunization with Monoclonal Antibody for Children 19 months and Younger](#)

V-Safe Registration for COVID-19 Vaccines

[V-safe registration](#) is now open to anyone who gets a 2023-2024 updated COVID-19 vaccine. Participants who enroll in V-safe within 6 weeks of vaccination will receive confidential health check-ins via text message or email to share how they feel after vaccination. V-safe helps CDC let others know what to expect following vaccination and increase confidence in vaccination decisions.

V-safe enrollment is now open for:

2023-2024 updated COVID-19 vaccine:

- Anyone 6 months and older

RSV vaccine for pregnant people (one approved vaccine):

- RSVpreF vaccine (ABRYSVO by Pfizer). ABRYSVO is the only RSV vaccine recommended during pregnancy.

RSV vaccine for older adults, aged 60 and older (two approved vaccines):

- RSVPreF3 vaccine (AREXVY by GSK)
- RSVpreF vaccine (ABRYSVO by Pfizer)

Help promote V-safe:

Please encourage vaccine recipients to enroll in V-safe. Adult caregivers and parents/guardians of children 6 months and older can enroll their dependents in V-safe to complete health check-ins on their behalf.

- Ask patients to sign up for V-safe using their smartphone, tablet, or computer at vsafe.cdc.gov.
- Share [V-safe factsheets](#) with instructions on how to register and complete health check-ins.
- Hang a [V-safe poster](#) near vaccination areas.

[Vaccine safety](#) monitoring is a top priority at CDC. V-safe is one of [several systems CDC uses to closely monitor the safety of vaccines](#) in the United States. The information gathered through V-safe helps CDC communicate timely and transparent information about the safety of vaccines to public health officials, healthcare providers, and the public.

News from the Institute for the Advancement of Family Support Professionals


The Institute for the Advancement of Family Support Professionals is happy to announce the launch of new Spanish features. Starting this month, all learners will have the opportunity to select Spanish as their preferred language in their [learner profile](#). If Spanish is selected, learners can take the **pre-assessment, certification exam**, and **read all testing information** in Spanish. Learners will have the ability to search for modules in either Spanish or English and modules that are also available in Spanish will be noted with an *¡Hola!* graphic on the module image. Digital badges and college credit are awarded regardless of the language in which a learner completes it.

Institute Learners can earn college credit with the University of Kansas School of Social Welfare

The University of Kansas School of Social Welfare, rooted in the Strengths Perspective, aims to transform lives and social contexts and promote social, economic, and environmental justice in Kansas, the nation, and the world. They do so by educating students to practice with integrity and competence; advancing the science and knowledge base of social work through scholarship and research; and participating in community-engaged service. You can earn college credits on the Institute! Complete details and more information on these opportunities can be found [HERE](#).

About the Institute

The Institute offers Family Support Professionals everywhere the opportunity to learn new skills and grow their careers. Through engaging, online modules and a personalized learning map feature, professionals take charge of their growth and advancement.



Upcoming State of Michigan (SOM) Holidays

February 19th (Presidents' Day)

Previously Released MIHP Updates

To review any previously released MIHP Weekly Updates, they can be found by [visiting the MIHP webpage Michigan.gov/MIHP](http://Michigan.gov/MIHP).

Bi-Weekly Update Topic Submission

If you have suggestions for topics to be addressed in future additions of the MIHP Weekly Update,

[please submit your ideas here.](#)

MDHHS Publications

[Sign up here to receive program updates and communications.](#)

Coordinator Directory

Please click here to access the most recent Coordinator Directory

[MIHP Coordinator Directory](#)

Our communication for the Maternal Infant Health Program has been streamlined to a single email address and phone number. Please forward all emails to MIHP@michigan.gov. For further assistance, contact the state office @ **1-833-MI4-MIHP (1-833-644-6447)**. Thank you.